Abatacept in the treatment of lupus

Expert Opinion on Biological Therapy

Volumn 12, Issue 10, 2012, Pages 1399-1406

  Hoi, Alberta Y ^a   Littlejohn, Geoffrey O ^b  

^a Department of Rheumatology   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

Abatacept; Biologic therapy; Co stimulatory blockade; Lupus

Indexed keywords

ABATACEPT; AZATHIOPRINE; CD28 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HLA B7 ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LOADING DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE;

ANIMALIA;

EID: 84866252310     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.713934     Document Type: Review

References (48)

1. Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004;20(5):539-50
2. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996;335(18):1369-77
3. Tsokos GC, Liossis SN. Immune cell signaling defects in lupus: Activation, anergy and death. Immunol Today 1999;20(18):119-24
4. Kammer GM. Immunotherapy tackles lupus. Nat Med 2002;8(12):1356-8
5. Foell J, Mittler RS. Costimulatory molecules as immunotherapeutic targets in systemic lupus erythematosus. Springer Semin Immunopathol 2006;28(2):153-62
6. Wiesendanger M, Stanevsky A, Kovsky S, Diamond B. Novel therapeutics for systemic lupus erythematosus. Curr Opin Rheumatol 2006;18(3):227-35
7. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174(3):561-9
8. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheumatism 2002;46(6):1470-9
9. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349(20):1907-15
10. Grammer AC, Lipsky PE. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 2002;46(6):1417-29
11. Vogelzang A, McGuire HM, Yu D, et al. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 2008;29(1):127-37
12. Bauquet AT, Jin H, Paterson AM, et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH- 7 cells. Nat Immunol 2009;10(2):167-75
13. Huang W, Sinha J, Newman J, et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002;46(6):1554-62
14. Kalunian KC, Davis JC, Merrill JT, et al. IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46(12):3251-8
15. Sidiropoulos P, Boumpas D. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004;13(5):391-7
16. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265(5176): 1225-7
17. Andrews BS, Eisenberg RA, Theofilopoulos AN, et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978;148(5):1198-215
18. Anders H, Schlondorff D. Murine models of renal disease: Possibilities and problems in studies using mutant mice. Exp Nephrol 2000;8(4-5):181-93
19. Davidson A, Aranow C. Lupus nephritis: lessons from murine models. Nature Publishing Group 2010;6(1):13-20
20. Chu EB, Hobbs MV, Wilson CB, et al. Intervention of CD4 + cell subset shifts and autoimmunity in the BXSB mouse by murine CTLA4Ig. J Immunol 1996;156(3):1262-8
21. Mihara M, Tan I, Chuzhin Y, et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000;106(1):91-101
22. Daikh DI, Wofsy D. Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001;166(5):2913-16
23. Orencia approved for rheumatoid arthritis. Health News 2006;12(3):2
24. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52(8):2263-71
25. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med 2006;144(12):865-76
26. Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58(4):953-63
27. Kremer JM, Russell AS, Emery P, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011;70(10):1826-30
28. Genovese MC, Becker J-C, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353(11):1114-23
29. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54(9):2807-16
30. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: A network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011(2):CD008794
31. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: Meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009;68(1):25-32
32. Ruperto N, Lovell DJ, Quartier P, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010;62(6):1792-802
33. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63(4):939-48
34. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62(10):3077-87
35. Gordon C. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 2003;42(11):1372-9
36. Yee C-S, Isenberg DA, Prabu A, et al. BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann Rheum Dis 2008;67(6):873-6
37. Wofsy D, Hillson JL, Diamond B. Alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012. [Epub ahead of print]
38. Liang MH, Schur PH, et al. Renal disease subcommittee of the American College of Rheumatology ad hoc committee on systemic lupus erythematosus response criteria, The American college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006;54(2):421-32
39. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365(20):1886-95
40. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64(4):1215-26
41. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61(9):1168-78
42. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9767):721-31
43. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63(12):3918-30
44. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991;34(8):937-44
45. Weiss JE, Sison CP, Ilowite NT, et al. Flares in pediatric systemic lupus erythematosus. J Rheumatol 2007;34(6):1341-4
46. Laustrup H, Voss A, Green A, Junker P. SLE disease patterns in a Danish population-based lupus cohort: An 8-year prospective study. Lupus 2010;19(3):239-46
47. Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010;19(8):949-56
48. Strand V. Clinical trial design in systemic lupus erythematosus: lessons learned and future directions. Lupus 200 4;13(5):406-11